Clinical Analysis of Adverse Drug Reactions

Principles of Clinical Pharmacology

Volumn , Issue , 2007, Pages 389-402

  Calis, Karim Anton ^a   Sidawy, Emil N ^b   Young, Linda R ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Shady Grove Adventist Hospital   (United States)

^c CARILION CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 65949103326     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369417-1/50065-1     Document Type: Chapter

References (67)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA 1998, 279:329-336.
2. Dartnell JG, Anderson RP, Chohan V, Galbraith KJ, Lyon ME, Nestor PJ, et al. Hospitalisation for adverse events related to drug therapy: Incidence avoidability and costs. Med J Aust 1996, 164:1111-1117.
3. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995, 274:S97-S99.
4. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, et al. The nature of adverse events in hospitalized patients. Results of the Har-vard Medical Practice Study II. N Engl J Med 1991, 324:947-959.
5. Shumock GT, Thornton JP, Witte WK. Comparison of pharmacy-based concurrent surveillance and med-ical record retrospective reporting of adverse drug reactions. Am J Hosp Pharm 1991, 48:801-813.
6. Beard K. Adverse reactions as a cause of hospital admission in the aged. Drugs Aging 1992, 2:525-529.
7. Prince BS, Goetz CM, Rihn TL, Olsky M. Drug-related emergency department visits and hospital admissions. Am J Hosp Pharm 1992, 49:275-282.
8. Cooper JW. Adverse drug reaction-related hospitaliza-tions of nursing facility patients: A 4-year study. South Med J 1999, 92:32-48.
9. Harb G, Alldredge B, Coleman R, Jacobson M. Phar-macoepidemiology of adverse drug reactions in hospi-talized patients with human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1993, 6:170-184.
10. Jick H. Adverse drug reactions: The magnitude of the problem. J Allergy Clin Immunol 1984, 74:471-475.
11. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Preven-tion Study Group. JAMA 1997, 277:507-511.
12. Johnson JA, Bootman JL. Drug-related morbidity and mortality: A cost-of-illness model. Arch Intern Med 1995, 155:1465-1470.
13. Leape LL. Preventing adverse drug events. Am J Health-Syst Pharm 1995, 52:1-9.
14. Karch FE, Lasagna L. Adverse drug reactions. A criti-cal review. JAMA 1975, 234:26-32.
15. ASHP guidelines on adverse drug reac-tion monitoring and reporting. Am J Hosp Pharm 1989, 46:77-80.
16. Kennedy DL, McGinnis T. Monitoring adverse drug reactions: The FDA's new Medwatch program. P and T 1993, 18:853-863.
17. Kennedy DL, McGinnis T. Monitoring adverse drug reactions: The FDA's new Medwatch program. P and T 1993, 18:1163-1168.
18. Hoigné R, Lawson DH, Weber E. Risk factors for adverse drug reactions -epidemiological approaches. Eur J Clin Pharmacol 1990, 39:295-305.
19. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay extra costs and attributable mortality. JAMA 1997, 277:27-34.
20. Rawlins MD, Thomas SHL Mechanisms of adverse drug reactions. Davies's textbook of adverse drug reactions 1998, 882-888. Chapman & Hall Medical, London. 5th ed. D.M. Davies, R.E. Ferner, D. Glanville H (Eds.).
21. Coombs RRA, Gell PGH Classification of allergic reactions responsible for clinical hypersensitivity and disease. Clinical aspects of immunology 1968, 1583-1585. Oxford University Press, Oxford. G. PGH (Ed.).
22. Mathews KP. Clinical spectrum of allergic and pseu-doallergic drug reactions. J Allergy Clin Immunol 1984, 74:221-227.
23. D'Arcy PF. Adverse reactions interactions with herbal medicines. Part 2. drug interactions. Adverse Drug React Toxicol Rev 1993, 12:406-411.
24. Uchegbu IF, Florence AT. Adverse drug events related to dosage forms and delivery systems. Drug Saf 1996, 14:487-499.
25. Wong YL. Adverse effects of pharmaceutical excip-ients in drug therapy. Ann Acad Med Singapore 1993, 22:825-831.
26. Napke E. Excipients adverse drug reactions and patients' rights. Can Med Assoc J 1994, 151:147-153.
27. Liss GM, Sussman GL, Deal K, Brown S, Cividino M, Siu S, et al. Latex allergy: Epidemiological study of 1351 hospital workers. Occup Environ Med 1997, 54:5-13.
28. Liss GM, Sussman GL. Latex sensitization: Occupa-tional versus general population prevalence rates. Am J Ind Med 1999, 35:104-110.
29. Clyne KE, German MR. Adverse drug reaction report-ing. Focus on cost and prevention. Pharm and Ther 1992, 17:1582-1587.
30. French DG. Avoiding adverse drug reactions in the elderly patient: Issues and strategies. Nurse Practi-tioner 1996, 21:127-137.
31. French DG. Avoiding adverse drug reactions in the elderly patient: Issues and strategies. Nurse Practi-tioner 1996, 90:963-968.
32. Carbonin P, Pahor M, Bernabei R Sgadari A. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 1991, 39:1213-1242.
33. Colley CA, Lucas LM. Polypharmacy: The cure becomes the disease. J Gen Intern Med 1993, 8:33-64.
34. Cohen JS. Avoiding adverse reactions. Effective lower-dose drug therapies for older patients. Geriatrics 2000, 55:114-118.
35. Cohen JS. Avoiding adverse reactions. Effective lower-dose drug therapies for older patients. Geriatrics 2000, 55:61-67.
36. Cohen JS. Avoiding adverse reactions. Effective lower-dose drug therapies for older patients. Geriatrics 2000, 55:3062-3073.
37. Melmon KL. Preventable drug reactions -causes and cures. N Engl J Med 1971, 284:1404-1413.
38. Gentry CA Rodvold KA. How important is therapeu-tic drug monitoring in the prediction and avoidance of adverse reactions? Drug Saf 1995, 12:1743-1755.
39. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991, 114:1382-1385.
40. Chutka DS, Evans JM, Fleming KC, Mikkelson KG. Drug prescribing for elderly patients. Mayo Clin Proc 1995, 70:2045-2048.
41. Mitchell AA, Lacouture PG, Sheehan JE, Kauffman RE, Shapiro S. Adverse drug reactions in children leading to hospital admission. Pediatrics 1988, 82:748-753.
42. Knight M. Adverse drug reactions in neonates. J Clin Pharmacol 1994, 34:992-1001.
43. Gupta A, Waldhauser LK. Adverse drug reactions from birth to early childhood. Pediatr Clin North Am 1997, 44:1359-1374.
44. Nightingale SL, Hoffman FA. Medwatch and adoles-cence. J Adolesc Health 1994, 15:706-711.
45. Merkatz RB, Temple R, Sobel S, Feiden K, Kessler DA. Women in clinical trials of new drugs. A change in Food Drug Administration policy. The Working Group on Women in Clinical Trials. N Engl J Med 1993, 329:1-51.
46. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: Analysis of 48 cohort studies. Br J Clin Pharmacol 1998, 46:787-796.
47. Kando JC, Yonkers KA, Cole JO. Gender as a risk factor for adverse events to medications. Drugs 1995, 50:636-640.
48. Tran C, Knowles SR, Liu BA, Shear NH. Gender dif-ferences in adverse drug reactions. J Clin Pharmacol 1998, 38:1200-1205.
49. Eichelbaum M, Kroemer H, Mikus G. Genetically determined differences in drug metabolism as a risk factor in drug toxicity. Toxicol Lett 1992, 64/65:659-662.
50. Lennard MS. Genetically determined adverse drug reactions involving metabolism. Drug Saf 1993, 9:29-34.
51. Eichelbaum M. Pharmacokinetic and pharmaco-dynamic consequences of stereoselective drug metabolism in man. Biochem Pharmacol 1988, 37:3377-3384.
52. Sheffer AL, Pennoyer DS. Management of adverse drug reactions. J Allergy Clin Immunol 1984, 74:1974-1976.
53. Danan G, Benichou C. Causality assessment of adverse reactions to drugs -I. A novel method based on the conclusions of international consensus meetings: Application to drug-indu. J Clin Epidemiol 1993, 46:356-367.
54. Miremont G, Haramburu F, Begaud B, Dangoumau Pere JC Adverse drug reactions: Physicians' opinions versus a causality assessment method. Eur J Clin Pharmacol 1994, 46:1696-1700.
55. Michel DJ, Knodel LC. Comparison of three algorithms used to evaluate adverse drug reactions. Am J Hosp Pharm 1986, 43:485-490.
56. Pere JC, Begaud B, Haramburu F, Albin H. Comput-erized comparison of six adverse drug reaction assess-ment procedures. Clin Pharmacol Ther 1986, 40:919-926.
57. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the proba-bility of adverse drug reactions. Clin Pharmacol Ther 1981, 30:555-557.
58. Hutchinson TA, Flegel KM, HoPingKong H, Bloom WS, Kramer MS, Trummer EG. Reasons for disagreement in the standardized assessment of suspected adverse drug reactions. Clin Pharmacol Ther 1983, 34:307-311.
59. Hutchinson TA, Lane DA. Assessing methods for causality assessment of suspected adverse drug reac-tions. J Clin Epidemiol 1989, 42:1949-1956.
60. Lortie FM. Postmarketing surveillance of adverse drug reactions: Problems and solutions. Can Med Assoc J 1986, 135:379-382.
61. Girard M. Conclusiveness of rechallenge in the interpretation of adverse drug reactions. Br J Clin Pharmacol 1987, 23:1236-1241.
62. Naranjo CA, Shear NH, Lanctot KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol 1992, 32:336-337.
63. Meyboom RHB, Egberts ACG, Edwards IR, Hekster YA, de Koning FHP, Gribnau FWJ. Principles of signal detection in pharmacovigilance. Drug Saf 1997, 16:833-834.
64. Corso DM, Pucino F, DeLeo JM, Calis KA, Gallelli JF. Development of a questionnaire for detecting poten-tial adverse drug reactions. Ann Pharmacother 1992, 26:839-842.
65. Reidenberg MM, Lowenthal DT. Adverse nondrug reactions. N Engl J Med 1968, 279:321-325.
66. Lewis JA. Post-marketing surveillance: How many patients? Trends Pharmacol Sci 1981, 2:301-306.
67. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure lactic acidosis due to fialuridine (FIAU) an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995, 333:40-64.